Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes

Abstract excerpt

No vaccine to protect against an estimated 238,000 shigellosis deaths per year is widely available. S. sonnei is the most prevalent Shigella, and multiple serotypes of S. flexneri, which change regionally and globally, also cause significant disease. The leading Shigella vaccine strategies are based on the delivery of serotype specific O-antigens. A strategy to minimize the complexity of a broadly-protective...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Clostridium difficile and Clostridium perfringens research
• Share to Escherichia coli research studies
• Share to Viral gastroenteritis research and epidemiology